Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-24
DOI
10.3389/fphar.2022.1057083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model
- (2022) Hong Jo Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
- (2022) Hoang Oanh Nguyen et al. Frontiers in Immunology
- Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options
- (2022) Charles B. Lau et al. Dermatologic Therapy
- Advances in the development of new biomarkers for Alzheimer’s disease
- (2022) Timofey O. Klyucherev et al. Translational Neurodegeneration
- Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study
- (2022) Hidehisa Saeki et al. Dermatology and Therapy
- PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?
- (2021) Frank S. Menniti et al. Frontiers in Neuroscience
- Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
- (2021) Daniela Mokra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea)
- (2021) Kathleen S. Hodgin et al. International Journal of Environmental Research and Public Health
- Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction
- (2021) Ioannis Mykoniatis et al. JAMA Network Open
- Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
- (2021) Elizabeth M. Berry-Kravis et al. NATURE MEDICINE
- Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
- (2021) Robert S Wallis et al. Lancet Respiratory Medicine
- Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure
- (2021) Nisha A. Gilotra et al. Circulation-Heart Failure
- Trends in kinase drug discovery: targets, indications and inhibitor design
- (2021) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
- (2021) Theerasuk Kawamatawong Frontiers in Pharmacology
- Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies
- (2021) Aleksandr V. Sokolov et al. PHARMACOLOGICAL REVIEWS
- PDE-7 Inhibitor BRL-50481 Reduces Neurodegeneration and Long-Term Memory Deficits in Mice Following Sevoflurane Exposure
- (2020) Yingle Chen et al. ACS Chemical Neuroscience
- Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the ‘Ph1‐negative Myeloproliferative Neoplasms Latium Group’
- (2020) MG Mazzucconi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
- (2020) Marta Joskova et al. Frontiers in Pharmacology
- Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
- (2020) Mauro Giorgi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
- (2020) Rachel HX Wong et al. JOURNAL OF BONE AND MINERAL RESEARCH
- An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases
- (2020) Si Chen et al. Expert Opinion on Drug Discovery
- UniProt: the universal protein knowledgebase in 2021
- (2020) et al. NUCLEIC ACIDS RESEARCH
- Genetic Association of Phosphodiesterases With Human Cognitive Performance
- (2019) Mark E. Gurney Frontiers in Molecular Neuroscience
- Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease
- (2019) Lutz Frölich et al. Alzheimers Research & Therapy
- Experimental and investigational phosphodiesterase inhibitors in development for asthma
- (2019) Polyxeni Ntontsi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders
- (2019) Mark E. Gurney et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
- (2019) Afroditi Boulougoura et al. Open Forum Infectious Diseases
- Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
- (2019) Amanda Krogmann et al. CNS SPECTRUMS
- Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
- (2019) George S. Baillie et al. NATURE REVIEWS DRUG DISCOVERY
- Role of Phosphodiesterase2A in Proliferation and Migration of Human Osteosarcoma Cells
- (2019) TAKU MURATA et al. ANTICANCER RESEARCH
- Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches
- (2019) Amy J. Tibbo et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease
- (2019) Nikolaos Tzoumas et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
- (2019) Leif Bjermer et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present)
- (2019) Agnieszka Zagórska EXPERT OPINION ON THERAPEUTIC PATENTS
- Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses
- (2019) Jennifer J. O'Brien et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R
- (2018) Emmanuel Paradis et al. BIOINFORMATICS
- PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery
- (2018) K-E Andersson BRITISH JOURNAL OF PHARMACOLOGY
- Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance
- (2018) Anton Pekcec et al. BRITISH JOURNAL OF PHARMACOLOGY
- Milrinone Dosing and a Culture of Caution in Clinical Practice
- (2018) Luke Yong Zheng Chong et al. Cardiology in Review
- Inhibitors of phosphodiesterase as cancer therapeutics
- (2018) Ting Peng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Asthma
- (2018) Alberto Papi et al. LANCET
- Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates
- (2018) Daniela Mokra et al. PEDIATRIC PULMONOLOGY
- Inhibitors of phosphodiesterases in the treatment of cough
- (2018) Juraj Mokry et al. RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
- Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
- (2018) David Brown et al. SCHIZOPHRENIA BULLETIN
- Orphan Drugs and Their Impact on Pharmaceutical Development
- (2018) Misty M. Attwood et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
- (2018) Heng Li et al. Frontiers in Pharmacology
- Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy
- (2017) Yasunori Nio et al. FASEB JOURNAL
- Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
- (2017) Eric Knott et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
- (2017) Charbel Moussa et al. Journal of Neuroinflammation
- Chronic obstructive pulmonary disease
- (2017) Klaus F Rabe et al. LANCET
- Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson’s Disease?
- (2017) Dominic Ngima Nthenge-Ngumbau et al. MOLECULAR NEUROBIOLOGY
- Caffeine for apnea of prematurity: Effects on the developing brain
- (2017) Anzari Atik et al. NEUROTOXICOLOGY
- DrugBank 5.0: a major update to the DrugBank database for 2018
- (2017) David S Wishart et al. NUCLEIC ACIDS RESEARCH
- Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient
- (2017) Donna M. Cartledge et al. Frontiers in Oncology
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
- (2016) Christopher J Edwards et al. ANNALS OF THE RHEUMATIC DISEASES
- Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats
- (2016) Dan Wan et al. BRAIN RESEARCH BULLETIN
- Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex
- (2016) Peter H. Schafer et al. CELLULAR SIGNALLING
- Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
- (2016) Hugo Geerts et al. Expert Review of Neurotherapeutics
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
- (2016) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
- (2016) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Second Messengers
- (2016) Alexandra C. Newton et al. Cold Spring Harbor Perspectives in Biology
- The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
- (2016) Gunnar Birgegård Current Hematologic Malignancy Reports
- Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
- (2016) Hugo Geerts et al. Expert Review of Neurotherapeutics
- Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis
- (2016) Selvakumar Subbian et al. Frontiers in Immunology
- Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model
- (2016) Selvakumar Subbian et al. EBioMedicine
- Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436
- (2015) Wataru Hamaguchi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A
- (2015) John P. Redrobe et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis
- (2015) Liang Chen et al. EUROPEAN UROLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
- (2015) R. Scott Turner et al. NEUROLOGY
- Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition
- (2015) Philip G. Jones et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Host-Directed Therapies for Tuberculosis: Figure 1.
- (2015) David M. Tobin Cold Spring Harbor Perspectives in Medicine
- Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells
- (2014) Kenichi Hiramoto et al. CELLULAR SIGNALLING
- PDE inhibitors currently in early clinical trials for the treatment of asthma
- (2014) Maria Gabriella Matera et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Resveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activity
- (2014) Michael Rouse et al. JOURNAL OF ENDOCRINOLOGY
- Advances in targeting cyclic nucleotide phosphodiesterases
- (2014) Donald H. Maurice et al. NATURE REVIEWS DRUG DISCOVERY
- The PDE4 Inhibitor HT-0712 Improves Hippocampus-Dependent Memory in Aged Mice
- (2014) Marco Peters et al. NEUROPSYCHOPHARMACOLOGY
- Atopic Dermatitis: Skin-Directed Management
- (2014) Megha M. Tollefson et al. PEDIATRICS
- Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition
- (2014) Liping Sun et al. PLoS One
- PDE2 Is a Novel Target for Attenuating Tumor Formation in a Mouse Model of UVB-Induced Skin Carcinogenesis
- (2014) Jamie J. Bernard et al. PLoS One
- Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study
- (2014) RameshR Rai et al. Saudi Journal of Gastroenterology
- The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
- (2013) Mathias Rask-Andersen et al. Annual Review of Pharmacology and Toxicology
- Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma
- (2012) Clara Curiel-Lewandrowski et al. CANCER
- Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
- (2012) Sung-Jun Park et al. CELL
- A Prospective, Controlled Phase II Study of Neoadjuvant Exisulind Therapy Before Radical Prostatectomy: Effect on Apoptosis
- (2012) Christopher J. Weight et al. UROLOGY
- Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway
- (2011) Vinh Q. Chau et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis
- (2011) Li-Chun Lisa Tsai et al. CURRENT OPINION IN PHARMACOLOGY
- Trends in the exploitation of novel drug targets
- (2011) Mathias Rask-Andersen et al. NATURE REVIEWS DRUG DISCOVERY
- Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
- (2011) Sharron H. Francis et al. PHYSIOLOGICAL REVIEWS
- Conserved expression and functions of PDE4 in rodent and human heart
- (2010) Wito Richter et al. BASIC RESEARCH IN CARDIOLOGY
- The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis
- (2010) Chris Rundfeldt et al. JOURNAL OF NEURAL TRANSMISSION
- Sildenafil Stops Progressive Chamber, Cellular, and Molecular Remodeling and Improves Calcium Handling and Function in Hearts With Pre-Existing Advanced Hypertrophy Caused by Pressure Overload
- (2009) Takahiro Nagayama et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104
- (2009) Ramaswamy Govindan et al. Journal of Thoracic Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now